Syneos Health UK Limited

Syneos Health UK Limited is the United Kingdom operating company of Syneos Health, a global biopharmaceutical solutions organization that combines clinical development services with medical affairs and commercial capabilities. The UK entity is registered in Farnborough, United Kingdom, and operates as part of the wider Syneos Health group, whose public-facing brand is presented simply as Syneos Health®. Syneos Health describes itself as "a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success." Its business spans the clinical-to-commercial continuum: it runs clinical trials and related development services, provides medical affairs support, and delivers commercial and consulting services to biopharmaceutical customers. The company states that it translates clinical, medical affairs and commercial insights into outcomes, and that it brings together professionals with a deep understanding of patient and physician behaviors and market dynamics. As part of the global group, the UK entity supports customers in the United Kingdom and internationally. Syneos Health emphasizes therapeutic depth, assembling specialized project teams, and an AI-driven approach to performance, connecting and harmonizing data to deliver actionable insights. The company reports that in the last five years it has helped to develop or commercialize a large share of novel drugs approved by the US Food and Drug Administration, including 96% of oncology drugs and 89% of central nervous system drugs. Syneos Health is led by an executive committee including Chief Executive Officer Costa Panagos, Chief Operating Officer Michael Brooks, Chief Financial Officer Michael Bonello, Chief Human Resources Officer Simon Bartle, Chief Medical Officer Dr. Greg Licholai, Chief Digital and Information Officer Mike Montello, General Counsel and Corporate Secretary Jon Olefson, Global Head of Corporate Communications & Marketing Kristen Spensieri, and Executive Chairman Colin Shannon. The group has received industry recognition, including being named one of Forbes' World's Best Management Consulting Firms and America's Best Management Consulting Firms, and a leader in Everest Group's 2025 Pharmacovigilance Operations PEAK Matrix®. The UK legal entity, Syneos Health UK Limited, is a subsidiary within the Syneos Health corporate structure. It is not separately listed on a stock exchange; the parent group was formerly publicly traded and is now privately held. The entity's role is to employ staff and contract with customers and partners in the United Kingdom as part of Syneos Health's global delivery network.

Syneos Health UK Limited is the United Kingdom operating entity of Syneos Health, a global biopharmaceutical solutions organization. The UK company is registered in Farnborough, United Kingdom, and forms part of the Syneos Health group's international network. The Syneos Health brand itself was created through the merger of two established life-sciences service providers: INC Research, a clinical research organization, and inVentiv Health, a commercial and medical affairs services company. The combined business adopted the Syneos Health name and positioned itself as the industry's first fully integrated biopharmaceutical solutions organization, spanning clinical development through commercialization. The UK legal entity, Syneos Health UK Limited, carries that brand into the United Kingdom market, employing local staff and contracting with customers and partners in the region. As part of the global group, the UK entity contributes to Syneos Health's clinical-to-commercial service offering. The company describes itself as "a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success," translating clinical, medical affairs and commercial insights into outcomes. Its work covers clinical trial execution, medical affairs, commercial services and consulting, supported by therapeutic-depth teams and an AI-driven approach to performance. Syneos Health has highlighted its contribution to drug development, stating that in the last five years it has helped to develop or commercialize a large share of novel drugs approved by the US Food and Drug Administration, including 96% of oncology drugs and 89% of central nervous system drugs. The group has also received external recognition, including being named one of Forbes' World's Best Management Consulting Firms 2026 and America's Best Management Consulting Firms for the 11th year in a row for Syneos Health Consulting, and being named a leader in Everest Group's 2025 Pharmacovigilance Operations PEAK Matrix® for both pre- and post-approval services. Leadership of the group includes Chief Executive Officer Costa Panagos, Chief Operating Officer Michael Brooks, Chief Financial Officer Michael Bonello, Chief Human Resources Officer Simon Bartle, Chief Medical Officer Dr. Greg Licholai, Chief Digital and Information Officer Mike Montello, General Counsel and Corporate Secretary Jon Olefson, Global Head of Corporate Communications & Marketing Kristen Spensieri, and Executive Chairman Colin Shannon. The group has also announced appointments such as Greg Licholai as Chief Medical Officer and Simon Bartle as Chief Human Resources Officer, and has advanced an AI-powered clinical ecosystem to optimize trial performance and speed decision-making. The parent group was formerly publicly traded and is now privately held; Syneos Health UK Limited itself is a subsidiary and is not separately listed. Its role is to serve as the group's UK legal and operational presence within Syneos Health's global delivery model.

• Syneos Health brand formed through the merger of INC Research and inVentiv Health, creating a fully integrated biopharmaceutical solutions organization.

• Syneos Health UK Limited registered in Farnborough, United Kingdom, as the group's UK operating entity.

• Syneos Health advances AI-powered clinical ecosystem to optimize trial performance and speed decision-making.

• Greg Licholai appointed Chief Medical Officer to advance next-generation drug development.

• Simon Bartle appointed Chief Human Resources Officer.

• Syneos Health named a leader in Everest Group's 2025 Pharmacovigilance Operations PEAK Matrix® for both pre- and post-approval services.

• Syneos Health named one of Forbes' World's Best Management Consulting Firms 2026.

A fully integrated biopharmaceutical solutions organization and CRO that accelerates customer success across the clinical-to-commercial continuum, combining therapeutic depth, AI-driven performance and specialized expertise.

• Clinical development and trial execution

  Full-service clinical research organization capabilities, including trial design, execution and performance optimization.

• Medical affairs

  Medical affairs services supporting biopharmaceutical customers across the product lifecycle.

• Commercial and consulting services

  Commercialization support and management consulting, including Syneos Health Consulting.

• Pharmacovigilance operations

  Pre- and post-approval pharmacovigilance services recognized by Everest Group.

• AI-powered clinical ecosystem

  AI-driven innovations connecting and harmonizing data to deliver precise, actionable insights.

• PatientGO

  Mobile app for patient engagement, named Best Mobile App for Patient Engagement in the 2026 MedTech Breakthrough Awards.

• Kinetic

  Intelligent HCP engagement solution, a finalist in the AI Innovation in Intelligent HCP Engagement category.

1. 1Syneos Health | Biopharma Solutions Organization & CROsyneoshealth.com
2. 2Who We Are | Syneos Healthsyneoshealth.com
3. 3Awards | Syneos Healthsyneoshealth.com
4. 4Our Leadership | Syneos Healthsyneoshealth.com
5. 5Syneos Health UK Limited (United Kingdom) - Wikidatawikidata.org